검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01)) Turnstone Biologics, Corp.·Advanced Solid Tumor ORR 28% |
|---|---|
Overview Program | Oncolytic Virus Injection(RT-01) |
Overview Company | Turnstone Biologics, Corp. |
Overview Modality | CGT |
Overview Target | Advanced Solid Tumor |
Overview Indication | Advanced Solid Tumor |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Phase I clinical trial of a recombinant oncolytic virus injection combined with PD-1 antibody-based gene therapy for recurrent head and neck cancer in China: An open-label study.. This study aims to evaluate the safety and preliminary efficacy of VT1093, an oncolytic recombinant herpes simplex virus type 1 (HSV-1) engineered to express a PD-1 monoclonal antibody, for the treatment of recurrent hea… |
Clinical Primary efficacy | ORR 28% |
Clinical ORR | 28% |
Clinical Result source | ClinicalTrials.gov NCT00289016 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | RT-01 (Oncolytic Virus Injection, Oncolytic Virus Injection(RT-01)) Turnstone Biologics, Corp.·Advanced Solid Tumor ORR 28% |
|---|---|
Overview Program | Oncolytic Virus Injection(RT-01) |
Overview Company | Turnstone Biologics, Corp. |
Overview Modality | CGT |
Overview Target | Advanced Solid Tumor |
Overview Indication | Advanced Solid Tumor |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Phase I clinical trial of a recombinant oncolytic virus injection combined with PD-1 antibody-based gene therapy for recurrent head and neck cancer in China: An open-label study.. This study aims to evaluate the safety and preliminary efficacy of VT1093, an oncolytic recombinant herpes simplex virus type 1 (HSV-1) engineered to express a PD-1 monoclonal antibody, for the treatment of recurrent hea… |
Clinical Primary efficacy | ORR 28% |
Clinical ORR | 28% |
Clinical Result source | ClinicalTrials.gov NCT00289016 |
Clinical Data Tier / Score | A · 37 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교